Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Dermatol Ther ; 35(12): e15969, 2022 12.
Artigo em Inglês | MEDLINE | ID: mdl-36346030

RESUMO

There is a paucity of data about the impact of systemic statins on vitiliginous lesions in non-segmental vitiligo (NSV) patients. To the best of our knowledge, no other studies have considered the correlation between lipid disturbances in vitiligo and vitiligo disease activity (VIDA) score. We sought in this study to evaluate the influence of simvastatin on vitiliginous lesions in NSV patients with dyslipidemia and study the correlation between VIDA score and lipid profile. This clinical trial started with 120 patients with NSV, 79 patients had dyslipidemia and received simvastatin 80 mg daily (till normalization of lipid profile or for 4 months, which came first) and only 63 patients continued till the end of the study. Lipid profile, vitiligo area severity index and VIDA were assessed before and 6 months after the end of simvastatin use. Serum total cholesterol (TC), triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), very low-density lipoprotein, and LDL/HDL ratio showed statistically significant increases in the NSV than in the control group (p Ë‚ 0.001). There was a statistically significant positive correlation between VIDA and serum levels of TC and LDL and with LDL/HDL ratio. Simvastatin significantly improved the lipid profile and significantly decreased VIDA (p < 0.011). Negative moderate correlation was found between the decrease in VIDA and duration of disease (r = -0.562, p < 0.001). Simvastatin 80 mg daily could be a helpful treatment for NSV patients with dyslipidemia, controlling the vitiligo activity and protecting against the hazardous effects of dyslipidemia. Better results can be obtained in patients with short duration of the disease.


Assuntos
Dislipidemias , Vitiligo , Humanos , Sinvastatina , Vitiligo/diagnóstico , Vitiligo/tratamento farmacológico , Dislipidemias/diagnóstico , Dislipidemias/tratamento farmacológico , Triglicerídeos , Lipoproteínas LDL/uso terapêutico
2.
J Dermatolog Treat ; 33(2): 1017-1022, 2022 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-32698635

RESUMO

BACKGROUND: Dermatochalasis is frequently associated with tissue ageing and leads to multiple functional and cosmetic issues. There are several possible medical and surgical treatments available, such as blepharoplasty and laser therapy. OBJECTIVE: The aim of this work was to evaluate plasma exeresis as a new technique for nonsurgical treatment of dermatochalasis of the upper eyelid. PATIENT AND METHODS: This clinical trial included 40 female patients with dermatochalasis. Each patient received 3 sessions of treatment with the technology of plasma exeresis with one-month interval. Final evaluation was performed three months after the last session by 2 blinded dermatologists and 2 ophthalmologists, lid laxity according to facial laxity rating scale (FLRS), marginal crease distance (MCD) before and after treatment and patient satisfaction score. RESULTS: There was a significant decrease in eye lid laxity (FLRS) after treatment where p < .001; 36 (90%) patients had change and 4 (10%) patients without change in general. There was a significant increase in MCD after treatment (p = .001). CONCLUSION: Plasma exeresis seems to improve appearance of the upper eyelid, without any serious adverse events and could be a valid solution for dermatochalasis especially in mild and moderate cases.


Assuntos
Blefaroplastia , Terapia a Laser , Blefaroplastia/métodos , Pálpebras/cirurgia , Feminino , Humanos , Terapia a Laser/métodos
3.
J Cosmet Dermatol ; 20(8): 2657-2666, 2021 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-33410249

RESUMO

BACKGROUND: Warts are common viral infection of the skin. Treating warts are still an ongoing challenge and no general agreement is reached, on the best treatment, despite different therapeutic approaches. Intralesional (IL) immunotherapy has recently been shown to be effective in treating various wart forms. AIMS: To assess the efficacy and safety of IL tuberculin, IL MMR vaccine, and intradermal (ID) BCG vaccination in treating viral warts. PATIENTS AND METHODS: Sixty patients with single or multiple warts were divided equally into three groups. Group A received IL MMR vaccine, and group B received IL tuberculin every 3 weeks (maximum 3 times). Group C received ID BCG vaccination in the arm with one month interval (maximum 3 times). Recurrence was followed up for 6 months. RESULTS: In group A, complete response occurred in 30%, partial response in 5%, and no response in 65%. In group B, complete response occurred in 45%, partial response in 20%, minimal response in 10% and no response in 25%. In group C, complete response occurred in 70%, partial response in 5%, minimal response in 5%, and no response in 20%. No recurrence was observed in group A and B but occurred in one patient in group C with the same lesion. CONCLUSIONS: Immunotherapy by IL tuberculin and ID BCG vaccination are safe, effective, and inexpensive techniques in treating all types of warts even if recalcitrant or multiple but immunotherapy by IL MMR vaccine has shown less effectiveness and less safety technique.


Assuntos
Vacina BCG , Verrugas , Vacina BCG/uso terapêutico , Humanos , Imunoterapia , Injeções Intralesionais , Vacina contra Sarampo-Caxumba-Rubéola/uso terapêutico , Tuberculina/uso terapêutico , Verrugas/tratamento farmacológico
4.
Am J Clin Pathol ; 155(3): 405-411, 2021 02 11.
Artigo em Inglês | MEDLINE | ID: mdl-32940336

RESUMO

OBJECTIVES: The association between Helicobacter pylori and chronic spontaneous urticaria (CSU) is controversial. Therefore, we aimed to directly diagnose H pylori by polymerase chain reaction (PCR) in gastric tissue from patients with CSU and to investigate the association between H pylori eradication therapy and CSU remission. METHODS: Twenty-seven of 72 patients with CSU who were positive for H pylori stool antigen and PCR in gastric biopsy specimens were randomized to receive either anti-H pylori treatment or placebo. RESULTS: Patients with H pylori were found to have significantly lower hemoglobin concentrations with microcytic hypochromic anemia and a significantly higher occurrence of dyspepsia symptoms. All H pylori-treated patients (except two) showed significant improvement of the urticaria itching and red wheals after 2 weeks of therapy compared with the placebo group (P < .001). The response rate to treatment was 85.7% (12 patients; 95% confidence interval, 64.3%-100.0%). The two patients who failed to eradicate H pylori had an H pylori strain resistant to amoxicillin. CONCLUSIONS: An association was observed between CSU and presence of H pylori infection in the gastric tissue. Whether this is a causal relationship or not remains to be discovered, but treatment of H pylori can significantly improve the symptoms of CSU.


Assuntos
Antibacterianos/uso terapêutico , Urticária Crônica/microbiologia , Infecções por Helicobacter/complicações , Infecções por Helicobacter/tratamento farmacológico , Adulto , Idoso , Amoxicilina/uso terapêutico , Claritromicina/uso terapêutico , Método Duplo-Cego , Quimioterapia Combinada/métodos , Feminino , Helicobacter pylori , Humanos , Masculino , Pessoa de Meia-Idade , Omeprazol/uso terapêutico , Projetos Piloto , Inibidores da Bomba de Prótons/uso terapêutico , Resultado do Tratamento , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...